Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Many Bright Ideas Technologies (OTCPK:MBGNF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Many Bright Ideas Technologies's Enterprise Value for the quarter that ended in Mar. 2026 was $0.10 Mil.
Many Bright Ideas Technologies's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Many Bright Ideas Technologies EV-to-EBIT Related Terms
Many Bright Ideas Technologies EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Many Bright Ideas Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Many Bright Ideas Technologies EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Many Bright Ideas Technologies's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Many Bright Ideas Technologies's EV-to-EBIT falls into.
Many Bright Ideas Technologies's current Enterprise Value is $0.31 Mil.
Many Bright Ideas Technologies's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Many Bright Ideas Technologies (MBGNF) has a EV-to-EBIT of -6.65 as of Aug. 31, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Many Bright Ideas Technologies and its competitors.
Is Many Bright Ideas Technologies' EV-to-EBIT too high?
Many Bright Ideas Technologies' current EV-to-EBIT is -6.65.
How does Many Bright Ideas Technologies' EV-to-EBIT compare to TMO and DHR?
Many Bright Ideas Technologies' EV-to-EBIT of -6.65 can be compared against companies in the Medical Diagnostics & Research industry. The industry median EV-to-EBIT is 23.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 23.15, based on 107 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Many Bright Ideas Technologies and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 23.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Many Bright Ideas Technologies's current EV-to-EBIT is -6.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Many Bright Ideas Technologies stock overvalued right now?
Many Bright Ideas Technologies (MBGNF) has a current EV-to-EBIT of -6.65. The current EV-to-EBIT is -6.65. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Many Bright Ideas Technologies (MBGNF), the current EV-to-EBIT is -6.65 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Many Bright Ideas Technologies Inc is a Canada-based life science company. It focused on the development and commercialization of genomic-based clinical laboratory diagnostic tests. The company is engaged in managing the license and rights to GeneFx Lung, which is a proprietary gene expression-based test for identifying those patients with early-stage non-small-cell lung cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBGNF has been successfully added to your 
